Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Stent thrombosis

Over the last year, it's been rare to utter the word "stent" without at least thinking "thrombosis," an uncommon but serious complication that's been on the minds of interventional cardiologists and patients alike.

11 May 2007

Key findings on new-generation stent

New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), offered clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.

11 May 2007

Off-label and untested use of drug-coated stents is common in U.S. practice

The off-label and untested use of drug-coated stents in the treatment of coronary artery blockage is common in U.S. practice, and ischemic complication rates are higher among patients receiving drug-coated stents for off-label indications, according to two studies in the May 9 issue of Journal of the American Medical Association.

9 May 2007

Adverse outcomes associated with unapproved uses of drug-coated stents

Research led by a team at the Methodist DeBakey Heart Center sheds light on what happens to high-risk patients who receive drug-coated stents off-label to open clogged arteries, as reported in today's Journal of the American Medical Association (JAMA) .

9 May 2007

Risk and outcome similar for bypass surgery, drug-eluting stents

Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.

20 Apr 2007

Long-term safety of drug-eluting stents in off-label use

Research presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent - a dangerous complication - and adherence and responsiveness to anti-clotting medication.

3 Apr 2007

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

Drug-eluting stent use in heart patients determined more by insurance type

If you want the best technology available to relieve blocked blood flow to the heart, the choice is a drug-eluting stent.

31 Mar 2007

First drug-eluting stent approved in Europe for most severe form of arterial disease in the leg

Cordis Endovascular, a division of Cordis Corporation, announced today that the Cypher Select Sirolimus-eluting stent received CE (Communite European) Mark in Europe for use in the treatment of severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions, which is the most severe form of arterial disease in the leg.

6 Sep 2006

One stent may be as good as two

Cardiologists increasingly use non-invasive methods to treat patients with diseased arteries that previously required open-heart surgery.

15 Mar 2006

Treatment of severe coronary artery disease with angioplasty/coronary stenting a viable alternative to bypass surgery

Severe stenosis (blockage) to the left main coronary artery - a condition commonly called a "widow-maker"- can result in sudden death. For nearly 30 years, the gold standard for treatment has been coronary artery bypass surgery (CABG).

1 Mar 2006

Drug-eluting stents significantly cut the rates of heart attack and repeat procedures

The use of medicated stents markedly improves the clinical outcomes of patients who develop blockages in aging veins surgically grafted onto the heart, according to a just-published study in the November 2005 issue of Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions.

18 Oct 2005

Cordis patents infringed by Boston Scientific Stents

Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe Cordis' pioneering Palmaz patent for balloon expandable stents

21 Jun 2005

First patient to test new treatment for peripheral arterial disease

For several years, crippling leg pain has prevented Joan Erickson from walking more than a block. If she paused to rest, she could walk a little more, but not enough to continue playing golf, her favorite pastime.

23 Mar 2005

Drug eluting stents as effective as vascular brachytherapy in preventing restenosis

After angioplasty is performed to widen clogged arteries, surgeons frequently use tiny wire-mesh tubes called stents to keep blood vessels open. But despite stenting, scar tissue can form to create new blockages -- a process called in-stent restenosis (ISR).

7 Mar 2005

Adenosine Therapeutics awarded grant to develop drug eluting stents to prevent restenosis

Adenosine Therapeutics announced today the award of a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health.

6 Dec 2004

Sirolimus drug-coated stent causes less inflammation than bare metal stents

In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill.

11 Nov 2004

Early reports of thrombosis after insertion of drug-eluting stent

Authors of a research letter in this week’s issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy.

21 Oct 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004